Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects
The purpose of this study is to compare once a week and once every other week darbepoetin alfa on the change in hemoglobin levels between the screening/baseline period and the evaluation period (weeks 25-30). This study will also assess the change in mean hemoglobin over 4 week intervals, instability of hemoglobin concentrations, darbepoetin alfa dosing requirements and red blood cell transfusions.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Double-Blind, Randomized, Comparative Study of Darbepoetin Alfa Given Once Weekly or Once Every Other Week for Treatment of Anemia in Hemodialysis Subjects|
- Comparison between once a week and once every other week darbepoetin alfa on the change in Hb level between the screening/baseline period and the evaluation period (weeks 25-30)
- Instability of Hb concentration during the evaluation period
- Weekly dose and frequency of darbepoetin alfa during the evaluation period
- RBC transfusions during the evaluation period.
|Study Start Date:||August 2002|
|Estimated Study Completion Date:||September 2003|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00119587